Showing 1 posts of 1 posts found.
Lilly has announced that its Alzheimer’s drug candidate solanezumab has failed its primary endpoints in two key phase III trials. …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement